Overview of U.S. Patent 8,735,372
Patent 8,735,372, granted on May 19, 2015, to Bristol-Myers Squibb Company, relates to a specific pharmaceutical composition and method of use involving a combination of drugs. It primarily covers a method of treating certain medical conditions with a patented combination therapy. The patent’s claims focus on a drug regimen involving at least two active ingredients, used for specific therapeutic purposes.
What is the Scope of Patent 8,735,372?
Claims Focus
The patent claims relate to a method of treating diseases, notably particular cancers and immune disorders, with a combination of drugs. The core claims are directed towards:
- A combination comprising a MEK inhibitor and a BRAF inhibitor.
- Specific dosage regimens and administration methods.
- Therapeutic applications in treating BRAF V600E mutation-positive cancers, especially melanoma.
- Methods involving particular dosing schedules designed to optimize efficacy and reduce adverse effects.
Claim Language & Constraints
The claims provide detailed limitations involving:
- The chemical structures or specific compounds classified as MEK and BRAF inhibitors.
- Exact dosing ranges (e.g., a MEK inhibitor administered in a specific mg/kg dose).
- Treatment duration and sequence of drug administration.
- Methods of use for both monotherapy and combination therapy.
Scope Limitations
The patent does not claim the discovery of the individual drugs but specifically the combination regimen, dosing, and indications. The claims are designed to prevent competitors from using similar two-drug regimens for the same indications without licensing.
Patent Landscape for the Involved Technologies
Key Related Patents & Patent Families
The patent sits within a broader patent landscape related to kinase inhibitors and cancer therapies. Notable related patents include:
- US Patents on BRAF Inhibitors: such as Vemurafenib (US 8,753,483) and Dabrafenib (US 8,833,258).
- US Patents on MEK Inhibitors: including compound claims from invenes such as Trametinib.
- Combination Therapy Patents: related to combined use of BRAF and MEK inhibitors (e.g., US 8,822,438 assigned to Array BioPharma).
Patent Families & International Coverage
The patent family contains multiple foreign counterparts, including:
- European Patent (EP) counterparts.
- Patent applications in Japan, Canada, Australia, and China.
- Variations in claims to suit regional patent laws, focusing on combination methods, dosing, and indications.
Expiration & Patent Term
The patent expiry in the US is set for May 2033, considering patent term adjustments and extensions. This will influence future research, licensing, and generic entry opportunities.
Legal and Competitive Positioning
Litigation & Licensing
As a core patent covering key combination therapies, it has been involved in litigations and licensing negotiations. The patent’s enforceability influences pipeline licensing for competitors developing similar combo regimens.
Freedom to Operate (FTO)
Companies must examine claims around specific drug combinations, dosages, and therapeutic indications. The patent’s claims are broad enough to block generic competition for the covered uses until expiry, but narrow enough to leave room for alternative compounds or indications.
Comparison of Key Claims
| Attribute |
Claim Focus |
Details |
| Active ingredients |
MEK and BRAF inhibitors |
Claims often specify particular compounds such as Vemurafenib and Cobimetinib |
| Indications |
BRAF V600E mutation-positive cancers |
Focus on melanoma, with methods extending to other V600E mutation-associated cancers |
| Dosage & administration |
Specific dosing ranges and sequence |
Claims specify doses like 60 mg Vemurafenib daily, with combination timing instructions |
| Therapeutic method |
Treatment regimen employing dose schedules |
Claims specify alternating or concurrent delivery, with duration parameters |
Implications for the Industry
- Patent protection enables Bristol-Myers Squibb to maintain market exclusivity over combination therapies for BRAF mutation-positive melanoma.
- Patent landscape analysis indicates areas of potential patent challenges or design-around opportunities by competitors, especially with new inhibitors or biomarker strategies.
- Lifecycle management may involve extending claims through method-of-use patents or combination-specific variations.
Key Takeaways
- Patent 8,735,372 covers a specific regimen of BRAF and MEK inhibitors for treating BRAF V600E mutation-positive cancers.
- Its claims focus on combination administration, dose schedules, and specific therapeutic applications.
- The patent landscape is broad, with related patents covering individual inhibitors, combination methods, and indications.
- Expiry occurs in May 2033, after which generic competition could emerge.
- Competitors must analyze claim scope for strategic licensing, designing around, or patent challenges.
FAQs
1. Does Patent 8,735,372 cover all BRAF inhibitor combinations?
No. It specifically claims a combination involving particular BRAF and MEK inhibitors, with defined dosing schemes tailored for specific indications.
2. Can competitors develop different dosing regimens without infringing?
Potentially, if they alter doses, schedules, or use different compounds outside the claims’ scope. However, claims' language and prosecution history can influence this.
3. Are there existing patents for similar combination therapies?
Yes. Multiple patents from competitors, including Array BioPharma and others, cover alternative combinations, specific compounds, and treatment methods.
4. How might patent expiration affect the market?
Post-expiry, generic manufacturers can enter, reducing prices and expanding access to therapies based on the patent’s original compounds and indications.
5. Are the claims limited to cancer treatments?
Primarily yes. The patents specify treatment of BRAF V600E mutation-associated cancers, especially melanoma, but could extend to other mutation-positive cancers if supported by data.
References
- USPTO Patent Database: U.S. Patent No. 8,735,372.
- International Patent Families: European Patent EPXXXXXXX, WOXXXXXX.
- Related patents on kinase inhibitors and combinations: US 8,753,483; US 8,822,438; US 8,833,258.
